Literature DB >> 8085477

Seroprevalence of human immunodeficiency virus infection among Chinese psychiatric patients in Taiwan.

C H Chen1.   

Abstract

Psychiatric patients were reported to have high risks of contracting HIV infection due to unstable mental symptoms and comorbidity of drug abuse. The author surveyed the seroprevalence of human immunodeficiency virus (HIV) infection among Chinese psychiatric patients hospitalized in 2 psychiatric hospitals in the Taipei City area, Taiwan. No positive case was identified among 834 psychiatric patients in 1 year's survey. The low seropositive rate of HIV infection among Chinese psychiatric patients may be explained by: the low prevalence of HIV infection in Taiwan and low HIV-related risk behaviors, especially rare comorbidity of drug abuse among Chinese psychiatric patients.

Entities:  

Mesh:

Year:  1994        PMID: 8085477     DOI: 10.1111/j.1600-0447.1994.tb01543.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 2.  What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review.

Authors:  Pamela Y Collins; Alea R Holman; Melvyn C Freeman; Vikram Patel
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

Review 3.  Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis.

Authors:  Elizabeth Hughes; Shaan Bassi; Simon Gilbody; Martin Bland; Fabiola Martin
Journal:  Lancet Psychiatry       Date:  2015-11-29       Impact factor: 27.083

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.